Cross-source identity
National Provider Identifier 1114428034 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|---|---|---|
| CMS Open Payments |
| NPI 1114428034 |
| 42 industry-payment records, 2024 |
| Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1114428034 | 119 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity 0941733a… | Canonical resolved node · 2 identifier(s) · 15 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $724 | 42 |
| Manufacturer | Amount | Records |
|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $136 | 8 |
| Otsuka America Pharmaceutical, Inc. | $105 | 5 |
| Novo Nordisk Inc | $87 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Ozempic(Semaglutide) | 58 | $88,327 |
| Farxiga(Dapagliflozin Propanediol) | 61 | $70,122 |
| Trelegy Ellipta(Fluticasone/Umeclidin/Vilanter) | 71 | $69,368 |
| Eliquis(Apixaban) | 68 | $62,387 |
| Mounjaro(Tirzepatide) | 34 | $60,254 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Bayer Healthcare Pharmaceuticals Inc. (NJ) | cms_open_payments |
| ← pays | Novo Nordisk Inc (NJ) | cms_open_payments |
| ← pays | Astrazeneca Pharmaceuticals Lp (DE) | cms_open_payments |
| ← pays | Abbvie Inc. (IL) | cms_open_payments |
| ← pays | Paratek Pharmaceuticals, Inc. (MA) | cms_open_payments |
| ← pays | Exact Sciences Corporation (WI) | cms_open_payments |
| ← pays | Glaxosmithkline, Llc. (PA) | cms_open_payments |
| ← pays | Boehringer Ingelheim Pharmaceuticals, Inc. (CT) | cms_open_payments |
| ← pays | Otsuka America Pharmaceutical, Inc. (MD) | cms_open_payments |
| ← pays | Pfizer Inc. (NY) | cms_open_payments |
| ← pays | Lilly Usa, Llc (IN) | cms_open_payments |
| ← pays | Astellas Pharma Us Inc (IL) | cms_open_payments |
| ← pays | Ardelyx, Inc. (MA) | cms_open_payments |
| ← pays | Mylan Specialty L.P. (WV) | cms_open_payments |
| ← pays | Phathom Pharmaceuticals, Inc. (NJ) | cms_open_payments |
| 5 |
| Phathom Pharmaceuticals, Inc. | $78 | 4 |
| Bayer Healthcare Pharmaceuticals Inc. | $54 | 3 |